Kardiologie up2date 2011; 7(4): 319-335
DOI: 10.1055/s-0030-1257108
Koronare Herzerkrankung und Atherosklerose
 
© Georg Thieme Verlag KG Stuttgart · New York

Aktueller Status der katheterinterventionellen Behandlung der koronaren Herzerkrankung

Felix  Vogt, Nikolaus  Marx
Further Information

Publication History

Publication Date:
02 February 2012 (online)

Abstract

Here, we describe current interventional techniques for the treatment of coronary artery disease focusing on recent drug-eluting stent (DES) developments. The introduction of DES in the beginning of the century revolutionized interventional cardiology by a dramatic improvement of in-stent restenosis (ISR) rates. However, in higher risk coronary lesions, clinical outcome is still severely crisscrossed by elevated ISR and often fatal stent thrombosis. Therefore, anew paradigm shifts are on the horizon with promising novel developments, e. g. biodegradable stents.

Literatur

  • 1 Mueller R L, Sanborn T A. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions.  Am Heart J. 1995;  129 146-172 DOI: 10.1016/0002-8703(95)90055-1
  • 2 Schlumpf M. 30 Jahre Ballonkatheter: Andreas Grüntzig, ein Pionier in Zürich.  Schweizerische Ärztezeitung. 2004;  85 3460
  • 3 Simsek C, Serruys P W. Developments in coronary artery stenting: primum non nocere.  Panminerva Med. 2011;  53 19-30
  • 4 Fischman D L, Leon M B, Baim D S et al., for the Stent Restenosis Study Investigators. A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease.  N Engl J Med. 1994;  331 496-501
  • 5 Cutlip D E, Chauhan M S, Baim D S et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.  J Am Coll Cardiol. 2002;  40 2082
  • 6 Roukoz H, Bavry A A, Sarkees M L et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.  Am J Med. 2009;  122 581 e1 – e10
  • 7 Costa M A, Simon D I. Molecular basis of restenosis and drug-eluting stents.  Circulation. 2005;  111 2257-2273
  • 8 Morice M C, Serruys P W, Sousa J E et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.  N Engl J Med. 2002;  346 1773-1780
  • 9 Stone G W, Ellis S G, Cox D A et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.  N Engl J Med. 2004;  350 221
  • 10 Serruys P W et al. RESOLUTE All Comers Trial. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.  N Engl J Med. 2010;  363 136-146
  • 11 Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.  N Engl J Med. 2006;  355 2113
  • 12 Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis.  Circulation. 2009;  119 2986
  • 13 Garg S et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer.  EuroIntervention. 2010;  6 233-239
  • 14 Grube E, Schofer J, Hauptmann K E et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.  JACC Cardiovasc Interv. 2010;  4 431-438
  • 15 Guagliumi G, Sirbu V, Musumeci G et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI).  Circ Cardiovasc Interv. 2010;  4 367-375 [Epub 2010 Jul 20]
  • 16 Byrne R A, Kastrati A, Massberg S et al., ISAR-TEST 4 Investigators. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease 3-year outcomes from a randomized clinical trial.  J Am Coll Cardiol. 2011;  58 1325-1331
  • 17 Massberg S, Byrne R A, Kastrati A et al., ISAR-TEST 4 Investigators. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: (ISAR-TEST 5) trial.  Circulation. 2011;  124 624-632 [Epub 2011 Jul 18]
  • 18 Virmani R et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?.  Circulation. 2004;  109 701-705
  • 19 Liu H T, Li F, Wang W Y et al. Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells.  Tex Heart Inst J. 2010;  37 194-201
  • 20 Yusuf R Z, Duan Z, Lamendola D E et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.  Curr Cancer Drug Targets. 2003;  3 1-19
  • 21 Huang S, Houghton P J. Mechanisms of resistance to rapamycins.  Drug Resist Updat. 2001;  4 378-391
  • 22 Farb A, John M, Acampado E et al. Oral Everolimus Inhibits In-Stent Neointimal Growth.  Circulation. 2002;  106 2379-2384 DOI: 10.1161/01.CIR.0000033973.06059.04
  • 23 Suzuki T, Kopia G, Hayashi S et al. Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model.  Circulation. 2001;  104 1188-1193 DOI: 10.1161/hc3601.093987
  • 24 Pfisterer M et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus baremetal stents.  J Am Coll Cardiol. 2006;  48 2584-2591
  • 25 Lüscher T F, Steffel J, Eberli F R et al. Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications.  Circulation. 2007;  115 1051-1058
  • 26 Moses J W, Leon M B, Popma J J et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.  N Engl J Med. 2003;  349 1315-1323
  • 27 Stone G W, Ellis S G, Cox D A et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.  Circulation. 2004;  109 1942-1947
  • 28 Roiron C, Sanchez P, Bouzamondo A et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials.  Heart. 2006;  92 6416
  • 29 Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.  Lancet. 2007;  370 937
  • 30 Stone G W, Midei M, Newman W et al. SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.  Circulation. 2009;  119 680-686 [Epub 2009 Jan 26]
  • 31 Smits P C, Kedhi E, Royaards K J et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).  J Am Coll Cardiol. 2011;  58 11-18 [Epub 2011 Apr 21]
  • 32 Byrne R A, Kastrati A, Massberg S et al., ISAR-TEST 4 Investigators. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.  J Am Coll Cardiol. 2011;  58 1325-1331
  • 33 Kim W J, Lee S W, Park S W et al., ESSENCE-DIABETES Study Investigators.. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.  Circulation. 2011;  124 886-892 [Epub 2011 Aug 1]
  • 34 Raber L, Wohlwend L, Wigger M et al. Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial.  Circulation. 2011;  123 2819-2828
  • 35 Garg P et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.  Circulation. 2008;  118 2277-2285
  • 36 Liistro F et al. Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 yrs.  J Am Coll Cardiol. 2010;  55 613-616
  • 37 Elezi S et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.  J Am Coll Cardiol. 2006;  48 1304-1309
  • 38 Godino C et al. Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry).  Am J Cardiol. 2008;  102 1002-1008
  • 39 Pfisterer M et al. Long-term benefit-risk balance of drug-eluting vs. Bare-metal stents in daily practice: Does stent diameter matter? Three-year follow-up of BASKET.  Eur Heart J. 2009;  30 16-24
  • 40 Sheiban I, Infantino V A, Colombo F et al. Very long-term results comparing a simple versus a complex stenting strategy in the treatment of coronary bifurcation lesions.  Catheter Cardiovasc Interv. 2009;  74 313-320
  • 41 Korn H V, Yu J, Ohlow M A et al. Interventional therapy of bifurcation lesions: a TIMI flow-guided concept to treat side branches in bifurcation lesions – a prospective randomized clinical study (Thueringer bifurcation study, THUEBIS study as pilot trial).  Circ Cardiovasc Interv. 2009;  2 535-542 [Epub 2009 Nov 10]
  • 42 Behan M W, Holm N R, Curzen N P et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study.  Circ Cardiovasc Interv. 2011;  4 57-64 [Epub 2011 Jan 4]
  • 43 Mehran R, Claessen B E, Godino C et al. ; Multinational Chronic Total Occlusion Registry. Long-term outcome of percutaneous coronary intervention for chronic total occlusions.  JACC Cardiovasc Interv. 2011;  4 952-961
  • 44 Ioannis I, Schmidt T, Bonizzoni E et al. Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents.  JAMA. 2005;  293 2126-2130
  • 45 Mauri L et al. Stent thrombosis in randomized clinical trials of drug-eluting stents.  N Engl J Med. 2007;  356 1020-1029
  • 46 Camenzind E, Steg P G, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.  Circulation. 2007;  115 1440-1455
  • 47 Holmes jr D R et al. Thrombosis and drug-eluting stents: an objective appraisal.  J Am Coll Cardiol. 2007;  50 109-118
  • 48 Mauri L et al. Stent thrombosis in randomized clinical trials of drug-eluting stents.  N Engl J Med. 2007;  356 1020-1029
  • 49 Brodie B, Pokharel Y, Fleishman N et al. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience.  JACC Cardiovasc Interv. 2011;  4 30-38
  • 50 Spaulding C et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction.  N Engl J Med. 2009;  355 1093-1104
  • 51 Dangas G D, Caixeta A, Mehran R et al., Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.  Circulation. 2011;  123 1745-1756 [Epub 2011 Apr 11]
  • 52 Byrne R A, Kastrati A, Massberg S et al., ISAR-TEST 4 Investigators. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease 3-year outcomes from a randomized clinical trial.  J Am Coll Cardiol. 2011;  58 1325-1331
  • 53 van Werkum J W, Heestermans A A, de Korte F I et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases.  Circulation. 2009;  119 828-834 [Epub 2009 Feb 2]
  • 54 Lagerqvist B, Carlsson J, Fröbert O et al. Swedish Coronary Angiography and Angioplasty Registry Study Group. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry.  Circ Cardiovasc Interv. 2009;  2 401-408 [Epub 2009 Sep 8]
  • 55 Brar S S et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis.  J Am Coll Cardiol. 2009;  53 1677-1689
  • 56 Mauri L et al. Drug-eluting or bare-metal stents for acute myocardial infarction.  N Engl J Med. 2008;  359 1330-1342
  • 57 Lee M S et al. Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention.  Am J Cardiol. 2010;  105 1076-1082
  • 58 Sheiban I, Omedé P, Biondi-Zoccai G et al. Update on dedicated bifurcation stents.  J Interv Cardiol. 2009;  22 150-155
  • 59 Scheller B et al. Positionspapier der DGK 2011: Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter.  Der Kardiologe. 2011;  DOI: 10.1007/s12181-011-0375-6
  • 60 Serruys P W, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.  J Am Coll Cardiol. 2011;  58 1578-1588
  • 61 Costa jr J R, Abizaid A, Costa R et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.  JACC Cardiovasc Interv. 2009;  2 422-427
  • 62 Tamburino C, La Manna A, Di Salvo M E et al. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial.  JACC Cardiovasc Interv. 2009;  2 197-204
  • 63 Lee C W, Park D W, Seung K B et al. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.  Am J Cardiol. 2011;  107 990-994 [Epub 2011 Feb 4]
  • 64 Verheye S, Agostoni P, Dubois C L et al. 9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions: The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study.  J Am Coll Cardiol. 2009;  53 1031-1039
  • 65 Amoroso G, van Geuns R J, Spaulding C et al. Assessment of the safety and performance of the STENTYS self-expanding coronary stent in acute myocardial infarction: results from the APPOSITION I study.  EuroIntervention. 2011;  7 428-436 DOI: 10.4244/EIJV7I4A71

Priv.-Doz. Dr. med. Felix Vogt

Medizinische Klinik I, Kardiologie
Universitätsklinik Aachen

Pauwelsstraße 30
52074 Aachen

Email: [email protected]